Drugs / Veligrotug
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01233895 | Sep 2006 → Sep 2008 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00791544 | Nov 2008 → Nov 2009 | liver cancer | Sanofi | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00774878 | Oct 2008 → Nov 2010 | breast neoplasm | Sanofi | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06384547 | May 2024 → May 2025 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06179875 | Jan 2024 → Apr 2025 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06021054 | Nov 2023 → Nov 2024 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05176639 | Dec 2021 → Jul 2024 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2008-10-27 | AbbVie | ImmunoGen, Inc. Earns $4 Million Milestone Payment with sanofi-aventis' Initiation of a Phase II Trial with AVE1642 abbvie.com ↗ |
| 2008-06-01 | AbbVie | ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with Targeted Anticancer Compounds IMGN242 and AVE1642 abbvie.com ↗ |
| 2007-12-08 | AbbVie | ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting with Targeted Anticancer Compounds IMGN901 (HuN901-DM1) and AVE1642 abbvie.com ↗ |
| 2006-10-04 | AbbVie | ImmunoGen Announces Initiation of Clinical Testing of AVE1642 Anticancer Compound in Collaboration with sanofi-aventis abbvie.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | veligrotug | “The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody” NCT05176639 ↗ |
| Known as | AVE1642 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00774878 ↗ |
| Known as | VRDN-001 | “Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor” NCT06021054 ↗2“The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody” NCT05176639 ↗ |
| Known as | WBP2363 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109357 ↗ |
| Action | Inhibit | “down-regulation of the insulin-like growth factor 1 receptor (IGF-1R)” NCT01233895 ↗ |
| Modality | Monoclonal antibody | “Anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody” NCT00774878 ↗ |
| Route | Intravenous | “administered intravenously” NCT00774878 ↗ |
| Target | IGF1R | “Anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody” NCT00774878 ↗ |